Vir Biotechnology granted Norgine an exclusive commercial license for tobevibart and elebsiran in Europe, Australia, and New Zealand.
Norgine to pay Vir Biotechnology EUR 55 million initially and up to EUR 495 million in milestones.
Both companies to share clinical development costs for the ongoing ECLIPSE program.
Completion of enrollment for ECLIPSE 3, a Phase 2b head-to-head trial to evaluate the treatment.
Commercial License Granted
Norgine obtained commercial rights for CHD treatment in specific regions from Vir Biotechnology.
Financial Benefits
Vir Biotechnology to receive EUR 55 million initially and could earn up to EUR 495 million in milestones, plus royalties.
Shared Development Costs
Norgine to contribute 25% towards clinical development costs in ECLIPSE program.
Innovative Treatment
The tobevibart and elebsiran combination is a novel therapy for chronic hepatitis delta with promising trial results.
- The agreement with Norgine strengthens Vir Biotechnology's global reach for CHD treatment.
- Financially, the reimbursement and milestone payments will support Vir's operations beyond 2027.
- Completion of enrollment in ECLIPSE 3 indicates progress in clinical trials for the treatment.
The partnership with Norgine marks a significant step in expanding the availability of innovative treatments for chronic hepatitis delta.